Baseline glycemic control, lipid profile and other metabolic parameters (renal and liver function) were similar between the two groups, except for higher levels of gamma-glutamyl transpeptidase (GGT) (p = 0.01) in the subcutaneous semaglutide group, possibly related to hepatic steatosis (Fig.S1h–u). Here, GGTLC1 is linked to fatty liver disease.